|
Company Shares of Rockwell Medical, Inc. Rally 5.86% - American Trade Journal |
 |
|
Shares of Rockwell Medical, Inc. (NASDAQ:RMTI) rose by 5.86% in the past week and 34.16% for the last 4 weeks. In the past week, the shares has outperformed the S&P 500 by 5.06% and the outperformance increases to 35.18% for the last 4 weeks. For the current week, the company shares have a recommendation consensus of Buy.
18.55% of the shares are held by the company Insiders, 28% of the shares are held by the institutions. Company shares has an average 3 month share volume of 564,811 and an average 10 day volume is recorded to be 898,625 Shares of the company have rallied 22.18% in the past 52 Weeks. On June 16, 2015 The shares registered one year high of $14.95 and one year low was seen on December 15, 2014 at $8.1. The 50-day moving average is $11.32 and the 200 day moving average is recorded at $10.48. S&P 500 has rallied 7.51% during the last 52-weeks. Shares of Rockwell Medical, Inc. (NASDAQ:RMTI) ended Friday session in red amid volatile trading. The shares closed down 0.2 points or 1.4% at $14.1 with 557,110 shares getting traded. Post opening the session at $14.44, the shares hit an intraday low of $13.96 and an intraday high of $14.4484 and the price vacillated in this range throughout the day. The company has a market cap of $707 million and the number of outstanding shares has been calculated to be 50,169,000 shares. The 52-week high of Rockwell Medical, Inc. (NASDAQ:RMTI) is $14.95 and the 52-week low is $8.095.
Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.
|